Literature DB >> 10595622

Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF.

B Obert1, H Tout, A Veyradier, E Fressinaud, D Meyer, J P Girma.   

Abstract

A protease present in plasma cleaves von Willebrand factor (vWF) at the peptide bond 842Tyr-843Met of the mature subunit. To quantify this vWF-cleaving protease activity in plasma we have developed a simple method based on the estimation by IRMA of the degradation of a constant amount of wild type recombinant vWF used as substrate, by serial dilutions of test plasma used as protease provider. vWFAg was estimated by two-site IRMA using as first coating antibody a monoclonal antibody (MoAb) whose epitope is localized on the C-terminal side of the cleavage site, and as second labeled antibody a pool of MoAbs specific for the N-terminal side. Because the proteolytic process leads to the progressive separation of the C- and N-terminal portions of the vWF subunit such an IRMA also shows a progressive apparent loss of vWFAg. In contrast, the levels of vWFAg estimated after proteolysis by regular IRMA remained essentially constant. Results obtained with this new method were compared with the analysis by SDS-agarose gel electrophoresis of the multimeric pattern of proteolyzed WT-rvWF and no significant difference was noted testing a series of 28 plasmas. As compared with normal pooled plasma, 14 normal individuals and 13 patients with various types of vWD had normal levels of protease activity (44-178%) by both methods. The validity of the method was confirmed by showing a lack of detectable protease activity in a patient with chronic relapsing thrombotic thrombocytopenic purpura. In conclusion our method appears as a useful tool for the quantification of the vWF-cleaving protease activity in plasma. Its sensitivity and specificity are similar to those of SDS-gel electrophoresis. However, this new IRMA has the major advantages of being much simpler and faster, and open to most research laboratories in the field.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595622

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

Review 1.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

Review 2.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  Measurement of ADAMTS13.

Authors:  Han-Mou Tsai
Journal:  Int Rev Thromb       Date:  2006

4.  Unresponsive thrombotic thrombocytopenic purpura in critically ill adults.

Authors:  Eric Mariotte; Alice Blet; Lionel Galicier; Michael Darmon; Nathalie Parquet; Etienne Lengline; David Boutboul; Emmanuel Canet; Richard Traineau; Benoît Schlemmer; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2013-04-03       Impact factor: 17.440

Review 5.  Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 6.  Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS): the new thinking.

Authors:  J Liu; M Hutzler; C Li; L Pechet
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

7.  In vivo analysis of the role of O-glycosylations of von Willebrand factor.

Authors:  Idinath Badirou; Mohamad Kurdi; Paulette Legendre; Julie Rayes; Marijke Bryckaert; Caterina Casari; Peter J Lenting; Olivier D Christophe; Cecile V Denis
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

8.  ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; AnnCharlotte Kristoffersson; Han-Mou Tsai; Wenhua Zhou; Ingemar Winqvist; Göran Oldaeus; Rolf Billström; Peter Björk; Lars Holmberg; Diana Karpman
Journal:  Eur J Pediatr       Date:  2006-12-24       Impact factor: 3.183

9.  Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay.

Authors:  Nicolas Beranger; Sandrine Benghezal; Bérangère S Joly; Sophie Capdenat; Adeline Delton; Alain Stepanian; Paul Coppo; Agnès Veyradier
Journal:  Res Pract Thromb Haemost       Date:  2020-12-15

10.  A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.

Authors:  Frédéric Adam; Caterina Casari; Nicolas Prévost; Alexandre Kauskot; Cécile Loubière; Paulette Legendre; Christelle Repérant; Dominique Baruch; Jean-Philippe Rosa; Marijke Bryckaert; Philip G de Groot; Olivier D Christophe; Peter J Lenting; Cécile V Denis
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.